FindTrial
Sign In

Medical Record Review

OTHER11 trials

Sponsors

Baylor Research Institute, Member Companies of the Opioid PMR Consortium, Jena University Hospital, Dana-Farber Cancer Institute, University of California, San Francisco

Conditions

Acute Care Service UtilizationAdvance DirectivesAdvanced Care PlanningBrain TumorCD4+ T LymphocytopeniaCancerCommunication SkillsCovid19

Phase 2

Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
Not yet recruitingNCT07682454
University of California, San FranciscoHepatocellular Carcinoma (HCC), Liver Cancer, Adult
Start: 2026-08-01End: 2030-02-01Target: 50Updated: 2026-07-02

Unknown Phase

Improving Diabetes Care:Effectiveness of Physician Profiling and Care Coordination by a Diabetes Resource Nurse
CompletedNCT00258674
Baylor Research InstituteDiabetes Mellitus
Start: 2000-01-01End: 2001-12-01Updated: 2026-03-03
Study to Eval Relation Btw Doctor/Pharmacy Shopping & Outcomes of Misuse, Diversion, Abuse, Addiction by Med Rec Review
CompletedNCT02667210
Member Companies of the Opioid PMR ConsortiumOpioid-Related Disorders, Opiate Addiction, Narcotic Abuse +1
Start: 2014-11-06End: 2017-06-21Updated: 2020-04-15
Regional Differences in Human Immunodeficiency Virus (HIV) Testing
CompletedNCT03158987
Jena University HospitalHIV Seropositivity, CD4+ T Lymphocytopenia
Start: 2017-06-01End: 2019-01-30Updated: 2021-09-02
Advance Care Planning: Communicating With Outpatients for Vital Informed Decision
CompletedNCT04660422
Dana-Farber Cancer InstituteAdvanced Care Planning, Shared Decision Making, Video Decision Aids +4
Start: 2020-12-15End: 2021-12-31Updated: 2022-07-05
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
RecruitingNCT06606028
University of California, San FranciscoSquamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin +1
Start: 2024-10-09End: 2029-12-30Target: 250Updated: 2025-12-12
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
RecruitingNCT06774027
University of California, San FranciscoHER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer +3
Start: 2025-10-08End: 2030-12-31Target: 100Updated: 2025-12-18
Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma
RecruitingNCT07418775
University of California, San FranciscoMeningioma of Brain, Meningioma, Brain Tumor
Start: 2026-01-16End: 2032-01-01Target: 3000Updated: 2026-05-19
Prospective Registry of Histotripsy for Soft Tissue Tumors
RecruitingNCT07470008
University of California, San FranciscoSoft Tissue Neoplasm, Soft Tissue Cancer, Soft Tissue Lesion
Start: 2026-01-29End: 2031-08-08Target: 200Updated: 2026-03-17
Acute Risk Monitoring for Oncology Therapy Regimen
CompletedNCT07601802
University of California, San FranciscoCancer, Acute Care Service Utilization
Start: 2017-07-01End: 2024-03-31Updated: 2026-05-22
Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities
RecruitingNCT07690579
University of California, San FranciscoProstate Cancer, Prostate Cancer Recurrent, Prostate Metastases
Start: 2026-03-31End: 2028-03-31Target: 350Updated: 2026-07-08

Related Papers

Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).
Journal of Clinical Oncology2025-05-28
Structural Barriers to Well-grounded Advance Care Planning for the Seriously Ill: a Qualitative Study of Clinicians' and Administrators' Experiences During a Pragmatic Trial.
2023-07-246 citations
Association of an Advance Care Planning Video and Communication Intervention With Documentation of Advance Care Planning Among Older Adults
JAMA Network Open2022-02-2439 citations